Ofatumumab pivotal trial said to confirm drug’s safety and efficacy

The safety and efficacy of the monoclonal antibody, ofatumumab, in the treatment of patients with refractory chronic lymphocytic leukaemia has been demonstrated in a pivotal clinical trial, according to its developers.

Location